Mirum Pharmaceuticals

MIRM

Market cap $4.95B

CRMD and MIRM are advancing niche therapies with strong launches, rising sales and strategic acquisitions shaping their growth.

MIRM shares rise this week on strong preliminary 2025 sales, upbeat 2026 outlook, key pipeline goals and business updates.

Mirum Pharmaceuticals, Inc. (MIRM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Meta Platforms is an advertising juggernaut with tremendous growth potential in the AI glasses market. Micron Technology is a steal of a deal among AI stocks.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

A director at Mirum Pharmaceuticals sold 5,000 shares of the company for $400,000 on Dec. 22. The entire transaction was direct, involving the exercise of vested stock options, immediately sold as shares.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum.

ESCONDIDO, Calif.--(BUSINESS WIRE)--Enthorin Therapeutics, LLC, a biotechnology company focused on circuit-modulating treatments for neurological and neurodevelopmental disorders, announced that its licensing partner for MRM-3379 (formerly ENT-3379), Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), in December, reported the initiation of the BLOOM Phase 2 clinical study evaluating MRM-3379 in Fragile X syndrome (FXS). MRM-3379 is an orally available, highly brain-penetrant, selective phosphodiestera.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference.

The AI bubble won't burst, but the S&P 500 won't deliver a fourth consecutive year of double-digit returns in 2026. Small-cap, mid-cap, and renewable energy stocks could perform well in the new year.